Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
JCI Insight ; 5(13)2020 07 09.
Article in English | MEDLINE | ID: covidwho-732194

ABSTRACT

BACKGROUNDFatal cases of COVID-19 are increasing globally. We retrospectively investigated the potential of immunologic parameters as early predictors of COVID-19.METHODSA total of 1018 patients with confirmed COVID-19 were enrolled in our 2-center retrospective study. Clinical feature, laboratory test, immunological test, radiological findings, and outcomes data were collected. Univariate and multivariable logistic regression analyses were performed to evaluate factors associated with in-hospital mortality. Receiver operator characteristic (ROC) curves and survival curves were plotted to evaluate their clinical utility.RESULTSThe counts of all T lymphocyte subsets were markedly lower in nonsurvivors than in survivors, especially CD8+ T cells. Among all tested cytokines, IL-6 was elevated most significantly, with an upward trend of more than 10-fold. Using multivariate logistic regression analysis, IL-6 levels of more than 20 pg/mL and CD8+ T cell counts of less than 165 cells/µL were found to be associated with in-hospital mortality after adjusting for confounding factors. Groups with IL-6 levels of more than 20 pg/mL and CD8+ T cell counts of less than 165 cells/µL had a higher percentage of older and male patients as well as a higher proportion of patients with comorbidities, ventilation, intensive care unit admission, shock, and death. Furthermore, the receiver operating curve of the model combining IL-6 (>20 pg/mL) and CD8+ T cell counts (<165 cells/µL) displayed a more favorable discrimination than that of the CURB-65 score. The Hosmer-Lemeshow test showed a good fit of the model, with no statistical significance.CONCLUSIONIL-6 (>20 pg/mL) and CD8+ T cell counts (<165 cells/µL) are 2 reliable prognostic indicators that accurately stratify patients into risk categories and predict COVID-19 mortality.FundingThis work was supported by funding from the National Natural Science Foundation of China (no. 81772477 and 81201848).


Subject(s)
CD8-Positive T-Lymphocytes , Coronavirus Infections/immunology , Hospital Mortality , Interleukin-6/immunology , Pneumonia, Viral/immunology , Aged , Area Under Curve , Betacoronavirus , COVID-19 , Coronavirus Infections/blood , Coronavirus Infections/mortality , Female , Humans , Interleukin-10/immunology , Interleukin-8/immunology , Logistic Models , Lymphocyte Count , Lymphopenia/blood , Lymphopenia/epidemiology , Male , Middle Aged , Multivariate Analysis , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/mortality , Prognosis , ROC Curve , Receptors, Interleukin-2/immunology , Retrospective Studies , SARS-CoV-2 , Tumor Necrosis Factor-alpha/immunology
SELECTION OF CITATIONS
SEARCH DETAIL